Molecular Insight Pharmaceuticals (MIPI) Inactive 10-Q2009 Q3 Quarterly report

Filed: 9 Nov 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absence, activitiesto, adequate, Africa, AG, allocation, American, area, ASCO, assist, assumption, ASU, aware, batch, biomedica, BMIPP, Braunschweig, breach, Canadian, capability, certified, CFO, cGMP, charge, civil, clarify, collect, collected, compassionate, compelling, competitor, compliant, Concurrent, construct, constructed, construction, consuming, costly, country, criminal, dedicated, deliverable, disadvantage, disclosuresfor, discretionary, dispose, durable, East, Eckert, edotreotide, eligible, eliminate, EMEA, environment, excretion, exemption, expedited, expiration, expire, exploiting, exploratory, EZN, face, fail, federal, flexibility, foreclose, foreclosure, foreign, foreseeable, forfair, forsubsequent, Germany, GmbH, Greece, grow, guarantee, guaranteed, halted, harm, incremental, IND, inherent, insolvency, insolvent, inspection, instrumentsto, introducing, IRB, irreparably, man, mandated, marketplace, MDS, Medizintechnik, merge, Middle, milestone, modification, MTD, NASDAQ, NCI, NDA, Nordion, North, notice, Nuclitec, objective, October, Oregon, Ottawa, outbound, ownership, paraganglioma, parent, percentage, Pharma, pioneer, policy, Portland, possession, preliminary, prevailing, prevent, preventing, priceto, priority, produce, producing, profile, prospectively, qualitative, quantitative, ratio, ready, refundable, reimbursable, relax, relaxing, reliance, render, renewable, repay, repayment, requiredfair, requiredinterim, restructure, retrospective, retrospectively, Russia, satisfy, scale, Setup, shorter, similarly, sixty, Society, Strahlen, strict, submission, suite, suspension, tandem, TCI, technical, termfair, Territory, tiered, title, tool, Turkey, uncertain, uncured, und, undergo, unforeseen, upfront, urinary, valuein, variable, vulnerable, withselling, world, written, Ziegler

Removed: cardiology, complementary, deliver, heart, historically, identified, innovative, item, launch, placement, profitable, recent, viable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

MIPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Molecular Insight Pharmaceuticals, Inc., a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2009 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of the period covered by this Form 10-Q.


Dated: November 6, 2009				/s/ Daniel L. Peters
				Daniel L. Peters
				President and Chief Executive Officer
				(Principal Executive Officer)

Dated: November 6, 2009				/s/ Charles H. Abdalian, Jr.
				Charles H. Abdalian, Jr.
				Chief Financial Officer
				(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.